Skip to main content Skip to main navigation menu Skip to site footer

Viral and non-viral causes in patients with hepatocellular carcinoma in Arifin Achmad General Hospital Riau Province during 2013-2017



Abstract

Background: Hepatocellular carcinoma (HCC) is the six most common cancer and the fourth leading cause of cancer-related death worldwide. Recent reports have suggested an increasing prevalence of HCC without evidence of hepatitis B and C infection (non-viral HCC).

Methods: This was a descriptive study with cross-sectional approach that aimed to describe the distribution of viral and non-viral risk causes of hepatocellular carcinoma cases at Arifin Achmad General Hospital (AAGH), Riau Province in the period of 2013-2017. Data were obtained from medical records of HCC patients using total sampling method.

Results: We included 129 cases of whom 64 (49,6%) were associated with viral causes and 65 (50,4%) were  non-viral HCC. Bivariate analyses showed that there was no age difference between viral and non-viral HCC patients but the prevalence of non-viral HCC was significantly higher in females than males (odds ratio [OR], 3,12 ; 95% confidence interval [CI], 1,2-8,1; p=0,016). In addition, patients with alpha-fetoprotein (AFP) <400 ng/mL were more frequently associated with non-viral HCC compared with those with elevated AFP ³400 ng/mL (OR, 3,71; 95%CI, 1,49-9,26; p=0,004).

Conclusion: There was an equal distribution of viral and non-viral causes in HCC cases at AAGH, Riau Province during 2013-2017. This suggests changing etiologies of HCC that may impact HCC surveillance.
Keywords: alpha-fetoprotein gender hepatitis B hepatitis C HCC surveillance non-viral

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  2. Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13(12):2140–51.
  3. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International. 2017;11(4):317–370.
  4. Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatol Res. 2012;42(1):1–14.
  5. Noda Y, Kawaguchi T, Kuromatsu R, Komukai S, Nakano M, Niizeki T, et al. Prognostic profile of patients with non‑viral hepatocellular carcinoma: A comparative study with hepatitis C virus‑related hepatocellular carcinoma using data mining analysis. Oncol Lett. 2019;18(1):227–36.
  6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.
  7. Liu P, Xie S-H, Hu S, Cheng X, Gao T, Zhang C, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget. 2017;8(40):68131–7.
  8. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
  9. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 2019;25(13):1550–9.
  10. Chaminda SR, Suchintha T, Anuk NM, Supun DA, Bhagya GM, Habarakada LCA, et al. Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology - a prospective study. BMC Gastroenterol. 2017;17(1):142.
  11. Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870.
  12. Loho IM, Hasan I, Rinaldi C, Dewiasty E, Gani RA. Hepatocellular carcinoma in a tertiary referral hospital in Indonesia: Lack of improvement of one-year survival rates between 1998-1999 and 2013-2014. Asian Pacific J Cancer Prev. 2016;17(4):2165–70.
  13. Jasirwan COM, Hasan I, Sulaiman AS, Lesmana CRA, Kurniawan J, Kalista KF, et al. Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia. Curr Probl Cancer. 2019
  14. Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatology Research. 2011;41(8):711–21.
  15. Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42(4):368–75.
  16. Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, et al. Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology. 2006;50(1):24–31.
  17. Huang S, Chang I, Hong C, Yen T, Chen C, Wu C, et al. Metabolic risk factors are associated with nonâ€hepatitis B nonâ€hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol Commun. 2018;2(6):747–59.
  18. Karin M. New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis Clin Med. 2018;1(1):21–8.
  19. Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(42):15532–8.
  20. Kim HS, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Current Gastroenterology Reports. 2019;21(4):7
  21. Farrell G. Insulin resistance, obesity, and liver cancer. Clin Gastroenterol Hepatol. 2014;12(1):117–9.
  22. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 2019;25(13):1550–9.
  23. Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, et al. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World J Gastroenterol. 2017;23(15):2763–70.
  24. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
  25. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641.
  26. Hennenfent KL, Girvan AC, Chaudhry A, Abada P, Sheffield K, Herren CK, et al. Overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): A real-world retrospective study. J Clin Oncol. 2017;35(15_suppl):e15658–e15658.

How to Cite

Arfianti, A., Putra, Z. D., Delhaldita, E., Sembiring, L. P., & Asputra, H. (2019). Viral and non-viral causes in patients with hepatocellular carcinoma in Arifin Achmad General Hospital Riau Province during 2013-2017. Bali Medical Journal, 8(3). https://doi.org/10.15562/bmj.v8i3.1584
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
2

Total
2

Share

Search Panel

Arfianti Arfianti
Google Scholar
Pubmed
BMJ Journal

Zulfatta Dwi Putra
Google Scholar
Pubmed
BMJ Journal

Ekral Delhaldita
Google Scholar
Pubmed
BMJ Journal

Ligat Pribadi Sembiring
Google Scholar
Pubmed
BMJ Journal

Hendra Asputra
Google Scholar
Pubmed
BMJ Journal